FGF21 and metabolic dysfunction-associated steatotic liver disease: A study showed that pharmacological administration of sulforaphane can increase the expression of FGF21 and reduce the phosphorylation level of p38 in liver, thus improving nonalcoholic fatty liver disease (34).